期刊文献+

长半衰期药物的生物利用度研究方法 被引量:2

Methodology on the Bioavailability of Drugs with Long Elimination Half-life
下载PDF
导出
摘要 本文介绍了长半衰期药物生物利用度研究的几种改进方法。长半衰期药物生物利用度试验中血样收集时间可不同于常规情况的3个以上半衰期,只须达到吸收完全即可,一般为24~36h。若吸收过程符合线性速率动力学,卷积回归法能够准确计算每个药动学参数,同时SIMA&KA和ESTF&KA计算程序又使求算大大简化,因而成为目前应用最为广泛也最为满意的方法。 The methods on the determination of the bioavailability for drugs with long elimination half-life were reviewed. All methods depended on the assumption of linear pharmacokinetics. Emphasis is laid on the regression methods of truncated areas-under-curves(AUC) to obtain estimate of bioavailability F, and the absorption rate constant Ka, without obeying the general rules of following blood or plasmal levels for at least three times the elimination half-life. It may take 24-36h to collect blood or plasma samples when the absorption was completed. Two PC-program , SIMF&KA and ESTE&KA , for the regression method of truncated areas can be used for the calculation of the AUC. So the method would be used widely to estimate the bioavailability of long elimination half-life.
作者 王海学 李端
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2000年第5期397-399,共3页 The Chinese Journal of Clinical Pharmacology
关键词 生物利用度 长消除半衰期 Cmax法 序贯用药 卷积回归法 药代动力学 bioavailability long elimination half-life
  • 相关文献

参考文献12

  • 11.U.K. Medicines Act: Note on application for product licences. Annex Ⅱto MAL 2, Department of Health and Social Security, London, UK, 1983. 被引量:1
  • 22.Tucker GT, Jackson PR, Storey GCA, et al. Bioavailability of amiodarone. Eur J Clin Pharmacol, 1984; 26:533~534. 被引量:1
  • 33.Urso R, Aarons L. Bioavailability of drugs with long elimination half-lives. Eur J Clin Pharmacol, 1983; 25:689~693. 被引量:1
  • 44.Bredberg ULF, Karlsson MO. In vivo evaluation of the semisimultaneous method for bioavailability estimation using controlled intravenous infusion as an extravascular route of administration. Biopharmaceutics Drugs Disposition, 1991; 12:583~597. 被引量:1
  • 55.Bredberg U, karlsson MO, Borgstrom L, et al. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther, 1992; 52: 239~248. 被引量:1
  • 66.Karlsson M, Lindberg FA. Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. Pharmacokinet Biopharmaceut, 1990; 18:293~311. 被引量:1
  • 77.Wijand H. The determination of the absolute bioavailability for drug substances with long elimination half-lives(with PC-programs for the method of truncated areas). Comput Meth program Biom, 1992; 39: 61~73. 被引量:1
  • 88.endrenyi L, Tothfalusi L. Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives. Int J Clin Pharmacol Ther, 1997; 35: 412~415. 被引量:1
  • 99.Gaudreault J, Potvin D, Lavigne J, et al. Truncated area under the curve as a measure of relatives extent of bioavailability: evaluation using esperimental data and Monte Carlo simulations. Phaym Res, 1998; 10:1621~1629. 被引量:1
  • 1010.Wijiand H. Updates of bioequivalence programs (including statistical power approximated by student?t). Comput Meth Program Biom, 1994; 42:275~281. 被引量:1

同被引文献24

  • 1杨进波.关于平行设计生物等效性试验几个问题的探讨[J].中国临床药理学杂志,2007,23(6):479-480. 被引量:4
  • 2汤光.现代药物学[M].北京:中国医药科技出版社,1996.511. 被引量:30
  • 3梁之彦.生理化学[M].上海:上海科技出版社,1990.350. 被引量:5
  • 4WHO技术报告系列,937号,附录7.多来源(仿制)药品:建立可互换性注册要求的指导原则[S].2006. 被引量:1
  • 5SFDA.药品注册管理办法[S].2007. 被引量:2
  • 6FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considera- tions IS]. 2003. 被引量:1
  • 7《化学药物制剂人体生物利用度和生物等效性研究技术指导原则》课题研究组.化学药物制剂人体生物利用度和生物等效性研究技术指导原则[S].2005. 被引量:1
  • 8Morais J A, I-obato Mdo R. The new European Medicines Agency guideline on the investigation of bioequivalence[J]. Basic Clin Phar- macol Toxicol, 2010, 106(3): 221. 被引量:1
  • 9Gehring R, Martinez M. Assessing product bioequivalence for ex- tended-release formulations and drugs with long half-lives [J]. J Vet Pharmacol Therap, 2012, 35(S1 ): 3. 被引量:1
  • 10Meir B, Kamal K M. Generic products of antiepileptic drugs: A per- spective on bioequivalence and interchangeability[J]. Epilepsia, 2010,51(6):941. 被引量:1

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部